Black Rock Inc. Atai Life Sciences N.V. Transaction History

Black Rock Inc.

$4.35 Trillion
Q2 2024

A detailed history of Black Rock Inc. transactions in Atai Life Sciences N.V. stock. As of the latest transaction made, Black Rock Inc. holds 1,306,903 shares of ATAI stock, worth $2.38 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,306,903

Previous 1,401,436 6.75%

Holding current value

$2.38 Million

Previous $2.76 Million 37.03%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	SELL	$1.27 - $2.6 $120,056 - $245,785	-94,533 Reduced 6.75%	1,306,903 $1.74 Million
Q1 2024 May 10, 2024	BUY	$1.5 - $2.19 $61,848 - $90,298	41,232 Added 3.03%	1,401,436 $2.76 Million
Q4 2023 Feb 13, 2024	SELL	$1.04 - $1.55 $1.15 Million - $1.71 Million	-1,103,839 Reduced 44.8%	1,360,204 $1.92 Million
Q3 2023 Nov 13, 2023	BUY	$1.27 - $2.28 $5,247 - $9,420	4,132 Added 0.17%	2,464,043 $3.18 Million
Q2 2023 Aug 11, 2023	BUY	$1.44 - $2.19 $488,318 - $742,650	339,110 Added 15.99%	2,459,911 $4.23 Million
Q1 2023 May 12, 2023	BUY	$1.17 - $2.7 $234,952 - $542,197	200,814 Added 10.46%	2,120,801 $3.84 Million
Q4 2022 Feb 13, 2023	BUY	$2.38 - $3.55 $887,471 - $1.32 Million	372,887 Added 24.1%	1,919,987 $5.11 Million
Q3 2022 Nov 14, 2022	BUY	$3.14 - $4.87 $943,921 - $1.46 Million	300,612 Added 24.12%	1,547,100 $5.12 Million
Q2 2022 Aug 12, 2022	BUY	$3.03 - $5.32 $649,901 - $1.14 Million	214,489 Added 20.78%	1,246,488 $4.54 Million
Q1 2022 May 12, 2022	BUY	$4.66 - $7.66 $351,629 - $578,000	75,457 Added 7.89%	1,031,999 $5.25 Million
Q4 2021 Feb 10, 2022	BUY	$6.82 - $17.8 $6.52 Million - $17 Million	956,542 New	956,542 $7.3 Million

Others Institutions Holding ATAI

# of Institutions

104

Shares Held

16.3M

Call Options Held

367K

Put Options Held

69.2K

View Full List

About ATAI Life Sciences N.V.

Ticker ATAI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 165,875,008
Market Cap $302M
Description
Atai Life Sciences N.V., through its subsidiary, ATAI Life Sciences AG, operates as a clinical-stage biopharmaceutical company. It engages in developing various therapeutic candidates that focuses on various mental health disorders. The company's therapeutic candidates include PCN-101, a subcutaneous formulation of R-ketamine for the treatment o...

More about ATAI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.

Account